Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune Inc.
Replimune Inc.
Indiana University
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Revolution Medicines, Inc.
M.D. Anderson Cancer Center
British Columbia Cancer Agency
Marengo Therapeutics, Inc.
NRG Oncology
Revolution Medicines, Inc.
Cedars-Sinai Medical Center
Dana-Farber Cancer Institute
Celldex Therapeutics
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Revolution Medicines, Inc.
Jules Bordet Institute
Revolution Medicines, Inc.
Ohio State University Comprehensive Cancer Center
Cambridge University Hospitals NHS Foundation Trust
National Institutes of Health Clinical Center (CC)
IGF Oncology, LLC
University of Illinois at Chicago
Yale University
Stanford University
Hadassah Medical Organization
National Institutes of Health Clinical Center (CC)
FeRx